4,6-disubstituted pyrimidines and their use as protein kinase inhibitors

Details for Australian Patent Application No. 2005256659 (hide)

Owner ALTANA Pharma AG

Inventors Stadlwieser, Josef; Maier, Thomas; Wirschun, Wolfgang; Graedler, Ulrich; Zuelch, Armin; Baer, Thomas; Beckers, Thomas; Ciossek, Thomas; Herdemann, Matthias

Agent Griffith Hack

Pub. Number AU-A-2005256659

PCT Pub. Number WO2006/000589

Priority 05102355.4 23.03.05 EP; 04103011.5 28.06.04 EP

Filing date 28 June 2005

Wipo publication date 5 January 2006

International Classifications

C07D 405/04 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

15 February 2007 PCT application entered the National Phase

  PCT publication WO2006/000589 Priority application(s): WO2006/000589

22 November 2007 Change of Name(s) of Applicant(s), Section 104

  ALTANA Pharma AG The name of the applicant has been changed to Nycomed GmbH

27 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005256662-Use of ether group-containing polymers as solubilizers

2005256653-Oral sustained release formulation of tedisamil with gastric retention properties